Form 4: Adaptive Biotechnologies Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp, sold 492,400 shares of common stock on July 21, 2026.

Summary

  • Option exercise/conversion: acquired 284,800 Common Stock at $6.55 ($1,865,440) on July 21, 2026; holds 1,304,458 after (Direct).
  • Open-market sale: disposed of 278,698 Common Stock at $21.72 ($6,053,321) on July 21, 2026; holds 1,025,760 after (Direct).
  • Open-market sale: disposed of 213,702 Common Stock at $22.12 ($4,727,088) on July 21, 2026; holds 812,058 after (Direct).
  • Option exercise/conversion: disposed of 284,800 Stock Option (right to buy) on July 21, 2026 (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $10,780,409 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Harlan S Robins — Officer (Chief Scientific Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-21Option exercise/conversionCommon Stock284,800$7$1.9M1,304,458
2026-07-21Open-market saleCommon Stock278,698$22$6.1M1,025,760
2026-07-21Open-market saleCommon Stock213,702$22$4.7M812,058
2026-07-21Option exercise/conversionStock Option (right to buy)284,800——0

Key Dates

DateDescription
2026-07-21Option exercise/conversion (284,800 shares)
2026-07-21Open-market sale (278,698 shares)
2026-07-21Open-market sale (213,702 shares)
2026-07-21Option exercise/conversion (284,800 shares)

Keywords

insider transaction, Form 4, ADPT, Adaptive Biotechnologies Corp, bearish, Harlan S Robins

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.